LTGO

Conviction 100HealthcareScan · Fri, Oct 2, 2026

Latigo Biotherapeutics, Inc. (LTGO) closed at $15.88 (-4.88%) on Oct 2, 2026. RSI(14) 32, -36.5% from its 52-week high, -13.0% year to date. Sector: Healthcare · Biotechnology.

LTGO$15.88-4.88%

ResistanceSupportVol 14Insider buy

Vol MA14 555.93K

Aug 7Aug 19Aug 31Sep 10Sep 22Oct 2

Latigo Biotherapeutics, Inc.Biotechnology

Price15.88

Change-4.88%

Gap+0.54%

Rel volume3.42×

Avg volume452.45K

Avg $ vol9M

SMA 2020.51

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 21.28

RSI (14)32

MACD hist-0.66

MACD cross—

Stoch %K / %D2 / 5

ADX (14)25

+DI / −DI13 / 30

RSI divergence—

MACD divergence—

ATR %10.77%

ADR %8.43%

52w high25.00

52w low15.88

From 52w high-36.50%

Above 52w low+0.00%

New 52w highNo

SqueezeOff

Bollinger width52.36%

%B0.07

Donchian pos2.03%

Donchian high24.80

Donchian low15.69

AVWAP (52w high)20.55

vs AVWAP high-22.75%

AVWAP (52w low)16.15

vs AVWAP low-1.67%

OBV trendDown

Chaikin MF (20)-0.40

Today vs 20d3.42×

Avg vol (14d)555.93K

Avg vol (20d)452.45K

Avg $ vol (20d)9M

Market cap1.05B

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank7.9

1 week-7.43%

1 month-27.08%

3 months—

6 months—

1 year—

YTD-13.01%

P/E—

P/B-3.81

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current1.15

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target57.67

Target upside263.28%

Analyst ratingBuy

Institutional—

Ent. value997.5M

Revenue—

Net income-25.8M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float21.74M

Float %32.8%

Short interest308.63K

Days to cover1.7d

Short volume84.8%

Squeeze score46 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank7.9 / 100

Group rank14 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance25.47

Support17.33

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LTGO

All disclosures →

No recent disclosed trades by Congress in LTGO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LTGO

Insider	Side	Shares	Value	Traded	Filed
Sanofi 10% owner · Common Stock · 2026-08-10	Convert	177.98K	—	2026-08-10	2026-08-12
Sanofi 10% owner · Series B Preferred Stock · 2026-08-10	Convert	494.8K	—	2026-08-10	2026-08-12
Sanofi 10% owner · Convertible Promissory Note · 2026-08-10	Convert	177.98K	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Common Stock · 2026-08-10	Convert	2.35M	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Series A Preferred Stock · 2026-08-10	Convert	3.15M	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Series A-2 Preferred Stock · 2026-08-10	Convert	1.82M	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Series A-2 Preferred Stock · 2026-08-10	Convert	866.02K	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Common Stock · 2026-08-10	Convert	4.98M	—	2026-08-10	2026-08-12
5AM Ventures VI, L.P. 10% owner · Series B Preferred Stock · 2026-08-10	Convert	1.48M	—	2026-08-10	2026-08-12
Sanofi 10% owner · Common Stock · 2026-08-10	Convert	494.8K	—	2026-08-10	2026-08-12

SEC filings

EDGAR filings in LTGO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.